Dechra Pharmaceuticals Plc is an animal health company based in United Kingdom. The company announced increased revenue by 19%. However, it also said that the animal health firm expected more challenges that would confront its current financial year.
Dechra operates globally with expertise in developing, manufacturing, sales, marketing and distribution of high quality products. These products are exclusively for veterinarians worldwide. The company operates under two divisions, the Pharmaceuticals and Services units.
The veterinary pharmaceutical company said that it would sell its other business units. The sale would include its National Veterinary Services arm, Dechra Laboratory Services and Dechra Specialist Laboratories. Patterson Companies would acquire the units for US$129.77 million in an all cash transaction.
In a statement released by Dechra CEO Ian Page, he said that although trading in Q4 was good, it did not offset US supply issues and the effect of poor weather experienced in the three months of the financial year.
Join the Conversation